Specimen Collection Cards Market Size & Share 2023 to 2032

Specimen Collection Cards Market Size

Specimen Collection Cards Market size was valued at USD 427 million in 2022 and is estimated to observe 5% CAGR from 2023 to 2032. Specimen collection cards are used for the collection, storage, and transportation of biological samples for laboratory analysis, preserving sample integrity. The increasing prevalence of infectious diseases worldwide has led to a higher demand for diagnostic tools.

For instance, infectious diseases contribute to over 52 million global deaths, posing a significant global health challenge, per the National Institute of Health (NIH). Therefore, the increasing prevalence of infectious diseases underscores the vital importance of prompt detection and intervention. Thus, specimen collection cards offer a secure and convenient method for collecting, transporting, and storing samples, facilitating efficient disease monitoring and control.
 

Furthermore, ongoing technological advancements in specimen collection cards enhance their efficiency and effectiveness in preserving various types of biological samples. Moreover, innovations in the design, materials, and coatings of these cards contribute to improved sample stability, facilitating more reliable laboratory analysis.
 

COVID-19 Impact

The COVID-19 upheaval elevated the specimen collection cards market, essential for swift and secure sample collection during widespread testing. These cards seamlessly adapted to the surge in point-of-care molecular diagnostics, estimated to reach USD 90 billion by 2032, enabling remote sample acquisition during lockdown. Moreover, their logistical efficiency and integration with diverse testing platforms played a crucial role in orchestrating an accessible and efficient testing landscape for COVID-19 and other infectious diseases.
 

Specimen Collection Cards Market Trends

The surge in point-of-care testing, a paradigm wherein diagnostic assessments occur in close proximity to the patient, has ignited a burgeoning need for specimen collection cards. These cards seamlessly integrate with point-of-care testing devices, facilitating swift and decentralized diagnostic processes. The inherent convenience of employing specimen collection cards alongside point-of-care devices positions them as indispensable tools in diverse healthcare landscapes, encompassing clinics, emergency departments, and remote locales, thereby propelling the flourishing trajectory of the market.
 

• Furthermore, molecular diagnostics are key in decoding diseases at the molecular level, with specimen collection cards acting as vital vessels to capture and preserve diverse biological samples.
   
• Amidst a growing emphasis on personalized healthcare and targeted therapies, there's a rising demand for precise molecular diagnostics, driving the pursuit of streamlined specimen harvesting methods.

Specimen Collection Cards Market Analysis

The market by product type is categorized into cotton & cellulose-based, fiber-based, and other product types. The cotton & cellulose-based segment garnered USD 230 million revenue size in the year 2022.
 

• These cards offer superior absorption properties, ensuring efficient sample collection and preservation. Additionally, their compatibility with a diverse range of biological specimens, coupled with eco-friendly attributes, has propelled widespread adoption.
   
• Moreover, the emphasis on sustainability in healthcare practices has further fueled the ascendancy of the cotton & cellulose-based segment, making it the preferred choice and a driving force behind market expansion.

Learn more about the key segments shaping this market

Download Free PDF

Based on specimen type, the specimen collection cards market is segmented into blood, saliva, urine, buccal cell, and other specimen types. The blood segment garnered USD 360 million revenue size in the year 2022.
 

• Blood specimens stand as a cornerstone in diagnostic testing, and specimen collection cards tailored for blood samples have exhibited superior reliability and compatibility.
   
• The pivotal role of blood in diverse medical analyses, coupled with the ease and efficiency of using specimen collection cards for blood-related diagnostics, has led to widespread adoption.
   
• This segment's ascendancy is further fueled by the continuous demand for comprehensive diagnostic solutions, solidifying its position as the driving force behind market progression.
   

Based on application, the specimen collection cards market unfolds into distinctive domains such as newborn screening (NBS), infectious diseases testing, therapeutic drug monitoring, forensics & research, wellbeing/health monitoring, and other applications. Notably, the newborn screening (NBS) enclave exhibited its prowess by amassing a substantial revenue of USD 124 million in the year 2022.
 

• Its ascendancy is propelled by mandated governmental initiatives, a surging prevalence of co-genital disorders, and advancements in technology.
   
• Specimen collection cards serve as indispensable tools in newborn screening, providing a streamlined approach to gather blood samples for prompt intervention. Moreover, the worldwide emphasis on proactive healthcare measures for infants serves as a bedrock, fortifying the NBS segment's dominance in the market.
   

Based on end-use, the specimen collection cards market unfolds its segmentation, encompassing the domains of hospitals & clinics, diagnostics centers, and other end-users. The hospitals & clinics segment garnered USD 233 million revenue size in the year 2022.
 

• The dominance of the segment is attributed to its high patient footfall, diverse testing requirements, and adherence to quality standards. These institutions play a crucial role in diagnostics, utilizing specimen collection cards for various tests.
   
• Moreover, centralized testing facilities, integration into larger healthcare networks, and involvement in research further enhance their influence, making hospitals key drivers of demand for specimen collection cards in the market.

U.S. specimen collection cards market accounted for USD 161 million revenue size in 2022 and is predicted to witness substantial market growth over the analysis timeline.
 

• The U.S. has taken a commanding position in the market, due to its advanced healthcare infrastructure, leadership in medical research, and strict adherence to regulatory standards.
   
• The country's extensive network of hospitals and clinics, coupled with its large and diverse patient population, fuels a constant demand for diagnostic tests, wherein specimen collection cards play a pivotal role.
   
• Additionally, the integration of healthcare networks facilitates the efficient utilization of specimen collection cards, consolidating the U.S.'s position as a key driver of demand and innovation in the market.
   

Specimen Collection Cards Market Share

The specimen collection cards industry is consolidated, with key players including Qiagen, PerkinElmer Inc., and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares. For instance, in November 2022, PerkinElmer Inc., a global health solutions leader, received FDA authorization to market the EONIS SCID-SMA assay kit for simultaneous detection of SMA and SCID in newborns. This approval expands PerkinElmer's product portfolio, strengthening its competitive edge in the market.
 

Some of the eminent market participants operating in the specimen collection cards industry include:

• Ahlstrom-Munksjö
• GenoTech Innovations Inc.
• Biocare Solutions Ltd.
• PolyTech Research Solutions
• QIAGEN
• CENTOGENE N.V.
• Innovate Diagnostics Technologies
• PerkinElmer Inc.
• Cytiva (Danaher Corporation)
• ARCHIMED Life Science GmbH
• FortiusBio
• Eastern Business Forms, Inc.
• DBS System SA
• GenTegra LLC
   

Specimen Collection Cards Industry News:

• In July 2020, PerkinElmer introduced a COVID-19 serology test based on dried blood spot collection cards, utilizing the GSP/DELFIA Platform, capable of processing 5,000 samples. This expansion of the product portfolio enhanced the company's competitive advantage in the market.
   
• In March 2020, Danaher Corporation acquired general electric company's life sciences division's Biopharma business. The acquired business operated under the name Cytiva within Danaher, functioning as an independent operating company within Danaher's Life Sciences segment. This strategic move granted Danaher Corporation a distinct competitive advantage in the Life Sciences sector.
   

Specimen collection cards market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product Type, 2018 – 2032 (USD Million)

• Cotton & cellulose-based
• Fiber-based
• Other product types

By Specimen Type, 2018 – 2032 (USD Million)

• Blood
• Saliva
• Urine
• Buccal cell
• Other specimen types

By Application, 2018 – 2032 (USD Million)

• Newborn screening (NBS)
• Infectious diseases testing
• Therapeutic drug monitoring
• Forensics & research
• Wellbeing/health monitoring
• Other applications

By End-use, 2018 – 2032 (USD Million)

• Hospitals & clinics
• Diagnostics centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East & Africa